Forte Biosciences, Inc. (FBRX) · Aug 27, 2026 · Acquisition

Forte Biosciences completes argenx’s $2.2B buyout as Nasdaq exit begins

$2.2B acquisition — $77/share cash deal completed; 87.13% tendered

The argenx acquisition closes at $77 per share, with 87.13% tendered. Forte now becomes private and exits Nasdaq.

The market already knew this was the expected endpoint. Forte had disclosed the merger agreement on July 26, 2026, and the $77-per-share tender offer began on August 6, so this filing confirms a scheduled transaction rather than introducing a new bid, price increase, or financing surprise. 〔0〕 〔1〕

Transaction detailFiling disclosure
Cash offer price$77.00 per share (Item 2.01)
Shares tendered, including Parent holdings87.13% of outstanding shares (Item 2.01)
Aggregate transaction fundingApproximately $2.2 billion, from Parent cash on hand (Item 2.01)
Closing dateAugust 27, 2026 (Item 2.01)

Execution was clean, but not unexpectedly so. The offer cleared its minimum-ownership condition, 87.13% of shares were tendered or already owned by Parent, and all remaining conditions were satisfied or waived. That removes closing risk, but the successful outcome was already embedded in the announced deal terms. 〔2〕

The filing ends Forte’s standalone public-company status. The merger made Forte a wholly owned subsidiary of argenx, while Nasdaq trading was suspended and delisting and deregistration steps were requested. 〔3〕 〔4〕

Management and governance now belong to the acquirer. All prior directors and officers departed at closing, replaced by Argenx’s merger-sub team, and Forte’s charter and bylaws were restated. 〔5〕

Net read: transaction completion at the already-known terms. This is a definitive acquisition close, not an incremental fundamental update; the appropriate scorecard is the factual event itself rather than a beat or miss versus expectations.

What to watch next

Form 25 delisting and Form 15 registration termination

Original filing on SEC EDGAR

Forte Biosciences completes argenx’s $2.2B buyout as Nasdaq exit begins | FBRX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.